|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma显示文摘 | Nicola Personeni Silvia Bozzarelli Tiziana Pressiani Lorenza Rimassa Maria Chiara Tronconi Francesco Sclafani Carlo Carnaghi Vittorio Pedicini Laura Giordano Armando Santoro | 2012 | Journal of Hepatology2012，，1： | 3 |
| 2 | Optimized management of advanced hepatocellular carcinoma:Four long-lasting responses to sorafenib显示文摘The therapeutic options for hepatocellular carcinoma (HCC) have been so far rather inadequate.Sorafenib has shown an overall survival benefit and has become the new standard of care for advanced HCC.Nevertheless,in clinical practice,some patients are discontinuing this drug because of side effects,and misinterpretation of radiographic response may contribute to this.We highlight the importance of prolonged sorafenib ad-ministration,even at reduced dose,and of qualitative and careful radiographic evaluation.We observed two partial and two complete responses,one histologically confirmed,with progression-free survival ranging from 12 to 62 mo.Three of the responses were achieved following substantial dose reductions,and a gradual change in lesion density preceded or paralleled tumor shrinkage,as seen by computed tomography.This report supports the feasibility of dose adjustments to allow prolonged administration of sorafenib,and highlights the need for new imaging criteria for a more appropriate characterization of response in HCC. | Giovanni Abbadessa Lorenza Rimassa Tiziana Pressiani Cynthia Carrillo-Infante Emanuele Cucchi Armando Santoro | 2011 | World Journal of Gastroenterology2011，17，19： | 2 |
| 3 | Targeted agents for second-line treatment of advanced hepatocellular carcinoma显示文摘Over the past ten years,sorafenib,a multikinase inhibitor,has been the standard of care for patients with unresectable hepatocellular carcinoma(HCC)and wellpreserved liver function.Recently,lenvatinib,a different multikinase inhibitor,was shown to be non-inferior to sorafenib,in terms of survival,while all other agents previously tested failed to prove non-inferiority(or superiority)when compared to sorafenib.Similarly,in the second-line setting,most investigational drugs failed to provide better survival outcomes than placebo.However,in the last 2 years three positive phase III trials have been published in this setting.The RESORCE trial,a phase III study evaluating regorafenib in HCC patients who experienced disease progression after first-line treatment with sorafenib,showed better outcomes with regorafenib compared to placebo.More recently,the phase III CELESTIAL trial demonstrated the superiority of cabozantinib,a multikinase inhibitor targeting vascular endothelial growth factor receptor,MET,and AXL,vs placebo in the second-and third-line setting in patients progressing on or intolerant to sorafenib.The survival benefits of a sustained anti-angiogenic inhibition were demonstrated also with ramucirumab in the phase III REACH-2 trial in patients previously treated with sorafenib and who had high baseline alpha-fetoprotein levels.Overall,the adverse events reported in these trials were in line with the known safety profiles of the tested agents.After nearly a decade of a certain degree of stagnation,we are now witnessing a period of novel therapeutic advances with multikinase inhibitors and monoclonal antibodies that will likely change the treatment scenario of HCC. | Nicola Personeni Tiziana Pressiani Silvia Bozzarelli Lorenza Rimassa | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 2 |
| 4 | Sorafenib in patientswith Child-Pugh class A and B advanced hepatocellular carcino-ma: a prospective feasibility analysis 显示文摘 | Pressiani T Boni C Rimassa L | 2013 | Annals of oncology2013，24，2： | 1 |
| 5 | Usefulness of alpha-feto-protein response in patients treated with sorafenib for advanced hepa- tocellular carcinoma显示文摘 | Personeni N Bozzarelli S Pressiani T | 2012 | J Hepatology2012，57，1： | 1 |
| 6 | A phase II randomized dose escalation trial of sorafenib in patients with advanced hepato- cellular carcinoma显示文摘 | Rimassa L Pressiani T Boni C | 2013 | Oncologist2013，18，4： | 1 |
| 7 | Sorafenib in patients with Child-Pugh class A and B advanced hepatocellu- lar carcinoma:a prospective feasibility analysis 显示文摘 | PRESSIANI T BONI C RIMASSA L | 2013 | Ann On- col2013，24，2： | 1 |
| 8 | Molecular determin-ants of outcome in sorafenib-treated patients with hepatocellular carcinoma显示文摘 | Personeni N Rimassa L Pressiani T | 2013 | J Cancer Res Clin Oncol2013，139，7： | 1 |
| 9 | A phase Ⅱ randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma显示文摘 | RIMASSA L PRESSIANI T BONI C | 2013 | Oncologist2013，18，4： | 1 |
| 10 | Usefulness of alpha- fetoprotein response in patients treated with sorafenib for ad- vanced hepatocellular carcinoma显示文摘 | Personeni N Bozzarelli S Pressiani T | 2012 | J Hepatol2012，57，1： | 1 |
| 11 | Usefulness of alpha - fetoprotein response in patients treated with sorafenib for advanced hepatoeellular carcinoma显示文摘 | Personeni N Bozzarelli S Pressiani T | 2012 | J Hepatol2012，57，1： | 1 |
| 12 | Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 显示文摘 | Personeni N Rimassa L Pressiani T | 2013 | J Cancer Res Clin Oncol2013，139，7： | 1 |
| 13 | Molecular determinants of outcome in sorafenib- treated patients with hepatocellular carcinoma显示文摘 | PERSONENI N RIMASSA L PRESSIANI T | 2013 | J Cancer Res Clin Oncol2013，139，7： | 1 |
| 14 | Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma显示文摘BACKGROUND A well-recognized class effect of immune checkpoint inhibitors(ICI)is immune-related adverse events(IrAEs)ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI.Deaths are reported in<5%of patients treated with ICI.There are,however,no reliable markers to predict the onset and severity of IrAEs.We tested the association between neutrophil-lymphocyte ratio(NLR)and platelet-lymphocyte ratio(PLR)at baseline with development of clinically significant IrAEs(grade≥2)in hepatocellular carcinoma(HCC)patients treated with ICI.AIM To test the association between NLR and PLR at baseline with development of clinically significant IrAEs(grade≥2)in HCC patients treated with ICI.METHODS Data was extracted from an international database from a consortium of 11 tertiary-care referral centers.NLR=absolute neutrophil count/absolute lymphocyte count(ALC)and PLR=platelet count/ALC.Cutoff of 5 was used for NLR and 300 for PLR based on literature.We also tested the association between RESULTS Data was collected from 361 patients treated between 2016-2020 across the United States(67%),Asia(14%)and Europe(19%).Most patients received Nivolumab(n=255,71%).One hundred sixty-seven(46%)patients developed at least one IrAE,highest grade 1 in 80(48%),grade≥2 in 87(52%)patients.In a univariable regression model PLR>300 was significantly associated with a lower incidence of grade≥2 IrAEs(OR=0.40;P=0.044).Similarly,a trend was observed between NLR>5 and lower incidence of grade≥2 IrAEs(OR=0.58;P=0.097).Multivariate analyses confirmed PLR>300 as an independent predictive marker of grade≥2 IrAEs(OR=0.26;P=0.011),in addition to treatment with programmed cell death ligand 1(PD-1)/cytotoxic T lymphocyte-associated protein-4(OR=2.57;P=0.037)and PD-1/tyrosine kinase inhibitor(OR=3.39;P=0.01)combinations.Antibiotic use was not associated with IrAE incidence(OR=1.02;P=0.954).Patients treated with steroids had a>2-fold higher incidence of grade≥2 IrAEs(OR=2.74;P<0.001),although 74%were prescribed steroids for the treatment of IrAEs.CONCLUSION Given that high baseline NLR and PLR are associated with a decreased incidence of IrAEs,lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI.This finding is in keeping with several studies in solid tumors that have shown that baseline NLR and PLR appear predictive of IrAEs. | Sirish Dharmapuri UmutÖzbek Hiren Jethra Tomi Jun Thomas U Marron Anwaar Saeed Yi-Hsiang Huang Mahvish Muzaffar Matthias Pinter Lorenz Balcar Claudia Fulgenzi Suneetha Amara Arndt Weinmann Nicola Personeni Bernhard Scheiner Tiziana Pressiani Musharraf Navaid Bertram Bengsch Sonal Paul Uqba Khan Dominik Bettinger Naoshi Nishida Yehia Ibrahim Mohamed Arndt Vogel Anuhya Gampa James Korolewicz Antonella Cammarota Ahmed Kaseb Peter R Galle Anjana Pillai Ying-Hong Wan Alessio Cortellini Masatoshi Kudo Antonio D’Alessio Lorenza Rimassa David James Pinato Celina Ang | 2023 | World Journal of Gastrointestinal Oncology2023，15，11： | 0 |
| 15 | 意大利贝加莫Villa d'Adda公共图书馆——防御建筑改造显示文摘TorredelBorgo是意大利贝加莫历史上最著名的防御建筑之一,历经三年的修复,最终被改造;VilladAdda公共图书馆,紧临博尔戈广场。中世纪高大精确的墙体、完整的结构以及位于村庄中心的地理位置,赋予了这座建筑最为深刻的历史纪念意义。该改造方案不仅有效保护了建筑的有结构,并且巧妙改变了空间的功能,为建筑重新注入活力。 | Gianluca Gelmini Andrea Pressiani | 2015 | 现代装饰2015，0，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员